Retatrutide Dosage Protocol (60 mg Vial)

Straightforward 12-week and 24-week planning for a 60 mg vial at 20 mg/mL.

• Retatrutide vials (60 mg each):
  • Phase 2, 12 weeks: Minimum 1 vial (56 mg required).
  • Phase 2, 24 weeks: Minimum 4 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 1 vial (48 mg required).
  • Phase 3, 24 weeks: Minimum 3 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 24 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 24 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (3 mL required).
  • Phase 2, 24 weeks: 2 bottles by volume (12 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (3 mL required).
  • Phase 3, 24 weeks: 1 bottle by volume (9 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 60 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3 mL of bacteriostatic water to produce 20 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 200 mcg.
• Vial size: The 60 mg label is total nominal vial content, not a weekly amount.
• Vial coverage: At the 2 mg research stage, one vial supplies 30 full weekly amounts. At the 12 mg research stage, one vial supplies 5 full weekly amounts. These are mass calculations, not vial storage or discard periods.

Use the retatrutide vial label to calculate concentration, U-100 units, and nominal yield without treating 60 mg as a weekly amount.

• Vial content: The label identifies 60 mg of total nominal retatrutide in the vial.
• Reconstitution: 60 mg divided by 3 mL equals a 20 mg/mL concentration.
• U-100 conversion: 0.01 mL equals 1 unit, and 1 unit contains 200 mcg at 20 mg/mL.
• Example conversion: 2 mg equals 10 units (0.10 mL); 4 mg equals 20 units (0.20 mL); 6 mg equals 30 units (0.30 mL); 8 mg equals 40 units (0.40 mL); 9 mg equals 45 units (0.45 mL); and 12 mg equals 60 units (0.60 mL).
• Interpretation: The 60 mg vial size changes the available number of full research amounts, not the study-defined target amounts or escalation schedule.

The cited trials used once-weekly subcutaneous administration with separate target-dose designs. Their dosing schedule began with a lower starting dose and planned dose increases rather than starting at the assigned target.

• Phase 2 obesity study: The 48-week trial evaluated 1 mg, 4 mg, 8 mg, and 12 mg target groups; the lower-start 12 mg arm progressed from 2 mg to 4 mg, 8 mg, and 12 mg.^[1][6][10]
• Phase 2 diabetes study: Once-weekly retatrutide was evaluated across several target groups in adults with type 2 diabetes.^[5][12]
• Phase 3 design: Published program methods describe 4 mg, 9 mg, and 12 mg targets reached through four-week escalation stages.^[2]
• Phase 3 evidence: TRANSCEND-T2D-1 reported efficacy and safety findings for once-weekly retatrutide in adults with type 2 diabetes.^[3]
• Evidence boundary: These are study schedules and arithmetic conversions, not individualized dosing instructions.

Document concentration, preparation, storage conditions, and every administration so the 60 mg calculations remain traceable.

• Preparation record: Label the vial 20 mg/mL and record the preparation date and exact diluent used.
• Storage record: Follow the supplied formulation and diluent instructions for temperature, light protection, and discard limits.
• Administration record: Log the study week, mass, U-100 units, mL, site, and observer initials.
• Agitation: Avoid shaking and unnecessary freeze-thaw exposure; protein and peptide stability depends on formulation-specific conditions.^[16]
• Sterile technique: Use a new sterile syringe and needle for every administration and place used sharps directly into an appropriate container.^[13][14][15]

A 60 mg vial contains a fixed total mass. Dividing that mass by a study amount shows the maximum number of complete administrations before storage limits, handling loss, and product-specific discard rules are considered.

• At 2 mg: 60 mg supplies 30 complete research amounts of 10 U-100 units (0.10 mL) each.
• At 4 mg: The vial supplies 15 complete research amounts of 20 units (0.20 mL) each.
• At 6 mg: The vial supplies 10 complete research amounts of 30 units (0.30 mL) each.
• At 8 mg: The vial supplies 7 complete research amounts of 40 units (0.40 mL), with 4 mg nominally remaining.
• At 9 mg: The vial supplies 6 complete research amounts of 45 units (0.45 mL), with 6 mg nominally remaining.
• At 12 mg: The vial supplies 5 complete research amounts of 60 units (0.60 mL) each.
• Course arithmetic: The displayed 24-week phase 2 sequence totals 200 mg and therefore requires at least four 60 mg vials. The displayed 24-week phase 3 sequence totals 180 mg and therefore requires at least three vials.^[1][2][3]
• Important limit: Nominal yield is mathematical. It does not establish sterility, beyond-use dating, potency after storage, or permission to retain a reconstituted vial for the entire calculated period.

Retatrutide is an investigational triple agonist engineered as a single molecule acting at the GIP, GLP-1, and glucagon receptors. Its pharmacology and prolonged exposure supported once-weekly investigation in clinical programs.^[4][7][8]

• GIP receptor activity: Glucose-dependent insulinotropic polypeptide signaling contributes to the compound’s incretin profile.
• GLP-1 receptor activity: Glucagon-like peptide-1 receptor signaling is associated with glucose-dependent insulin secretion, gastric emptying, and appetite-related pathways.
• Glucagon receptor activity: This third receptor component distinguishes retatrutide from single- and dual-receptor incretin medicines and contributes to its metabolic research rationale.^[4][7][8]
• Balanced molecule design: Preclinical and translational work characterized receptor potency, pharmacokinetics, and metabolic effects before the human dose-ranging trials.^[4]
• Page scope: The receptor discussion explains why the compound was studied; it does not convert mechanistic findings into a recommendation for use.

Clinical research evaluated weight, glycemic, cardiometabolic, liver, pharmacokinetic, and safety outcomes in defined study populations. Results should be read with the assigned target group, escalation method, and follow-up period.

• Obesity phase 2: The randomized study followed participants for 48 weeks and reported dose-related body-weight changes across the studied target groups.^[1]
• Type 2 diabetes phase 2: Investigators evaluated glycated hemoglobin, body weight, adverse events, and other metabolic measures.^[5][12]
• Phase 3 diabetes trial: TRANSCEND-T2D-1 reported glycemic and body-weight outcomes at 40 weeks in adults with type 2 diabetes.^[3]
• Study registration: ClinicalTrials.gov documents the randomized phase 2 obesity protocol, eligibility criteria, interventions, and planned outcomes.^[6]
• Supplementary methods: Trial appendices provide details that a headline result cannot, including estimands, missing-data methods, subgroup analyses, and adverse-event tables.^[10][12]
• Liver research: A randomized phase 2a substudy evaluated changes in liver fat among participants with metabolic dysfunction-associated steatotic liver disease.^[11]
• Cardiovascular context: Incretin-based research also considers heart rate, blood pressure, lipids, and broader cardiovascular risk, but outcomes cannot be generalized outside the studied designs.^[9]

The clinical dose escalation schedule was a study-design feature, not evidence that every participant should reach the highest target. Trials used a defined first dose, gradual dose increases, and active safety monitoring.

• Starting amount: Participants in the lower-start obesity arm began at 2 mg once weekly, and planned increases occurred at four-week intervals.^[1]
• Phase 3 progression: Published methods describe stepwise movement through 2 mg, 4 mg, 6 mg, 9 mg, and, when assigned, 12 mg targets.^[2][3]
• Retatrutide side effects: Nausea, diarrhea, vomiting, and constipation were among the gastrointestinal adverse events reported in the controlled programs.^{[1][3][5][12]}
• Escalation period: Gastrointestinal events were more frequent during dose escalation in the phase 2 obesity study and were generally mild to moderate.^[1]
• Heart rate: Dose-dependent increases in heart rate were observed in phase 2 research, with values declining after a peak during follow-up.^[1]
• Interpretation: Adverse-event frequencies belong to the cited populations, products, exposure periods, and monitoring procedures; they are not a safety guarantee for other contexts.

The vial strength and the study amount answer different questions. Sixty milligrams describes total material in the container; a row such as 4 mg describes the mass assigned per weekly administration in a specific trial stage.

• Same amount, different strength: A 4 mg research amount remains 4 mg whether calculated from a 5 mg, 20 mg, or 60 mg vial. Only the concentration and withdrawal volume can differ.
• Concentration controls units: At 20 mg/mL, every milligram occupies 0.05 mL, or 5 U-100 units. Multiplying the milligram amount by five gives the displayed unit value.
• Final volume matters: The 3 mL final volume is part of this page’s calculation. Changing the diluent volume changes mg/mL, units, and mL, so every related field must be recalculated together.
• Do not infer frequency: A larger vial does not create a more frequent schedule. The cited human programs used once-weekly subcutaneous administration.^[1][2][3][5]
• Do not infer duration: The number of mathematical administrations in a vial is not a validated storage duration or beyond-use period.

The clinical programs used subcutaneous administration. Any laboratory or institutional procedure should define equipment, training, aseptic technique, site selection, documentation, and waste handling.^[13][14][15]

• New equipment: Use a new sterile syringe and needle for every administration and each separate vial entry.
• Surface preparation: Clean the vial stopper and selected site according to the governing procedure, and allow antiseptic to dry.
• Injection site rotation: Rotate documented subcutaneous injection sites instead of repeatedly using one location.^[14]
• Volume check: Confirm both the U-100 marking and the equivalent mL before administration; syringe units are volume markings, not peptide international units.
• Immediate disposal: Place used needles and syringes directly into an approved sharps container without recapping unless the governing procedure specifically requires another method.^[13][15]
• Recordkeeping: Log the amount, units, volume, time, site, vial identifier, and any observation required by the research plan.

A strength label alone cannot establish stability after reconstitution. Storage must follow documentation for the exact supplied formulation, diluent, container, and preparation conditions.

• Before reconstitution: Keep the vial dry, protected from light, and within the documented temperature range.
• After reconstitution: Refrigerate only when directed for the exact preparation and record the documented discard limit.
• Gentle mixing: Add diluent slowly down the vial wall and gently swirl or roll until dissolved; do not shake.
• Freeze–thaw exposure: Repeated freezing and thawing can affect peptide or protein stability, and the outcome depends on formulation-specific factors.^[16]
• Visual inspection: Follow the governing procedure for any change in clarity, color, particles, container integrity, or labeling.
• Yield is not shelf life: Thirty calculated 2 mg withdrawals do not mean a prepared vial remains suitable for 30 weeks.

These frequently asked questions clarify the 60 mg retatrutide dosage schedule, the reconstitution guide, and the relationship between vial strength and published research.

• How much bacteriostatic water is used on this chart? The page uses 3 mL, creating 20 mg/mL.
• How many micrograms are in one U-100 unit? At 20 mg/mL, 0.01 mL contains 0.2 mg, or 200 mcg.
• How many units equal 2 mg? Ten units, which is 0.10 mL.
• How many units equal 12 mg? Sixty units, which is 0.60 mL.
• Does a 60 mg vial mean a 60 mg dose? No. Sixty milligrams is total nominal vial content. The cited clinical trials evaluated much smaller once-weekly target amounts.^[1][2][3][5]
• Why are there two dosage tables? The phase 2 and phase 3 programs used different target-group designs, so the schedules are presented separately rather than merged.^[1][2][3]
• Is the assigned target the same as a maintenance dose? Some search pages use “maintenance dose,” but the cited trials assigned target groups within controlled protocols. This page uses target dose to avoid implying a general recommendation.^[1][2][3][5]
• Can nominal vial yield determine storage time? No. Yield is arithmetic; storage and discard limits must come from the exact product and preparation documentation.
• Is this individualized medical advice? No. The chart is an educational translation of published research schedules into concentration, U-100 units, mL, vial yield, and supply planning.

This 60 mg retatrutide dosage page translates published human research schedules into strength-specific concentration, U-100 units, mL, nominal vial yield, and supplies. It does not establish an individualized regimen, product stability period, or recommendation for human use.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.